Claudia Pena-Rossi

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase ib, double‐blind, placebo‐controlled, dose‐escalating trial

Maria Dall’Era, Eliza F. Chakravarty, Daniel J. Wallace et al. · Arthritis & Rheumatism · 2007 · 292 citations

Life Sciences, Immunology, Pharmacology +16

Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis

Paul Emery, Juan Rondon, Janie Parrino et al. · Lara D. Veeken · 2018 · 124 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus

Claudia Pena-Rossi, Marina Stanislav, V. V. Yakusevich et al. · Lupus · 2009 · 111 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Clinical trial: a multicentre, randomized, double‐blind, placebo‐controlled, dose‐finding, phase II study of subcutaneous interferon‐β‐1a in moderately active ulcerative colitis

Claudia Pena-Rossi, Stefan Schreiber, G Golubović et al. · Alimentary Pharmacology & Therapeutics · 2008 · 48 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +17

Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension

Gerd R Burmester, Vibeke Strand, Andrea Rubbert‐Roth et al. · RMD Open · 2019 · 13 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17